文献速递胸部肿瘤

肺神经内分泌肿瘤:分子景观、治疗挑战及诊断与管理策略

Pulmonary neuroendocrine neoplasms: the molecular landscape, therapeutic challenges, and diagnosis and management strategies.
PubMed 文献 · Lancet Oncol · 2025-01-01

肺神经内分泌肿瘤涵盖从高分化低级别类癌到高级别低分化大细胞神经内分泌癌(LCNEC)和小细胞肺癌(SCLC)的异质性肿瘤。SCLC发病率下降而其他肺神经内分泌肿瘤全球发病率上升。分子与测序技术进展可能影响未来分类和分期,但罕见性导致前瞻性研究匮乏,LCNEC最佳治疗未明,推荐基于SCLC和NSCLC指南外推。

要点

  • 肺神经内分泌肿瘤涵盖高分化类癌至低分化LCNEC和SCLC,异质性强。
  • SCLC发病率下降,其他肺神经内分泌肿瘤全球发病率上升。
  • LCNEC可靶向基因改变少,最佳治疗未明,推荐基于SCLC和NSCLC指南外推。

核心结论

  • 肺神经内分泌肿瘤分子与测序技术进展可能影响未来分类和分期,进而改善辅助或转移 setting 的管理指南。

研究设计与样本

  • 本文为综述,探讨肺神经内分泌肿瘤的流行病学、诊断、分期、分子景观、生物标志物、临床结局、治疗格局及未来方向。

主要发现

  • SCLC发病率下降,而其他肺神经内分泌肿瘤全球发病率在过去数十年上升。
  • 肺神经内分泌肿瘤罕见,针对肺部的前瞻性研究匮乏,尤其在高分化类癌和LCNEC中。
  • 与非小细胞肺癌(NSCLC)靶向治疗的成功相反,肺高级别神经内分泌癌通常仅有少量可靶向基因改变。
  • LCNEC的最佳治疗未明,治疗推荐基于SCLC和NSCLC患者管理指南的外推。

局限性

  • 肺神经内分泌肿瘤罕见,针对肺部的前瞻性研究匮乏,尤其在高分化类癌和LCNEC中。
  • LCNEC最佳治疗未明,治疗推荐基于SCLC和NSCLC指南外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lung neuroendocrine neoplasms are a group of diverse, heterogeneous tumours that range from well-differentiated, low-grade neuroendocrine tumours-such as typical and atypical carcinoids-to high-grade, poorly differentiated aggressive malignancies, such as large-cell neuroendocrine carcinoma (LCNEC) and small-cell lung cancer (SCLC). While the incidence of SCLC has decreased, the worldwide incidence of other pulmonary neuroendocrine neoplasms has been increasing over the past decades. In addition to the standard histopathological classification of lung neuroendocrine neoplasms, the introduction of molecular and sequencing techniques has led to new advances in understanding the biology of these diseases and might influence future classifications and staging that can subsequently improve management guidelines in the adjuvant or metastatic settings. Due to the rarity of neuroendocrine neoplasms, there is a paucity of prospective studies that focus on the lungs, especially in rare, well-differentiated carcinoids and LCNECs. In contrast with the success of targeted therapies in non-small-cell lung cancer (NSCLC), high-grade neuroendocrine carcinomas of the lung often only have a few specific targetable gene alterations. Optimal therapy for LCNECs is not well defined and treatment recommendations are based on extrapolating guidelines for the management of patients with SCLC and NSCLC. This Review explores the epidemiology, diagnosis, and staging of lung neuroendocrine neoplasms to date. In addition, we focus on the evolving molecular landscape and biomarkers, ranging from tumour phenotypes to functional imaging studies and novel molecular biomarkers. We outline the various clinical outcomes, challenges, the treatment landscape, ongoing clinical trials, and future directions.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Sen T, Dotsu Y, Corbett V, et al. Pulmonary neuroendocrine neoplasms: the molecular landscape, therapeutic challenges, and diagnosis and management strategies. Lancet Oncol. 2025. PMID: 39756451. doi:10.1016/S1470-2045(24)00374-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。